DelveInsight’s, “Cutaneous Squamous Cell Carcinoma Pipeline Insight, 2023” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Cutaneous Squamous Cell Carcinoma pipeline landscape. It covers the Cutaneous Squamous Cell Carcinoma pipeline drug profiles, including Cutaneous Squamous Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Cutaneous Squamous Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Cutaneous Squamous Cell Carcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Cutaneous Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Cutaneous Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Cutaneous Squamous Cell Carcinoma Pipeline Report

 

• DelveInsight’s Cutaneous Squamous Cell Carcinoma Pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Cutaneous Squamous Cell Carcinoma treatment.

 

• The leading Cutaneous Squamous Cell Carcinoma Companies includes Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.

 

• Promising Cutaneous Squamous Cell Carcinoma Pipeline Therapies includes Cemiplimab, IBI318, STP705, Pembrolizumab, PEP005, and others.

 

• The Cutaneous Squamous Cell Carcinoma companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous Squamous Cell Carcinoma R&D. The Cutaneous Squamous Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma. 

 

To explore more information on the latest breakthroughs in the Cutaneous Squamous Cell Carcinoma Pipeline treatment landscape of the report, click here @ Cutaneous Squamous Cell Carcinoma Pipeline Outlook

 

Cutaneous Squamous Cell Carcinoma Overview

 

Cutaneous squamous cell carcinoma (SCC) is a common type of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin — the horny protein that makes up skin, hair and nails. Cutaneous SCC is an invasive disease, referring to cancer cells that have grown beyond the epidermis. SCC can sometimes metastasize and may prove fatal. More than 90% of cases of SCC are associated with numerous DNA mutations in multiple somatic genes.  Mutations in the p53 tumor suppressor gene are caused by exposure to ultraviolet radiation (UV), especially UVB (known as signature 7). Other signature mutations relate to cigarette smoking, ageing and immune suppression (eg, to drugs such as azathioprine).

 

Latest Developmental Activities in the Cutaneous Squamous Cell Carcinoma Treatment Landscape

 

• Henlius has received clinical trial approvals for HLX07 in the treatment of solid tumors in Chinese mainland, the United States, and Taiwan China. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

 

• RM-1995, developed by Rakuten Medical using its IlluminoxTM platform, is an antibody-dye conjugate comprised of a monoclonal antibody specific for cell-surface interleukin 2 (IL-2) receptor α-chain (CD25) and IRDye® 700DX (IR700), a light-activatable dye. RM-1995 photo immunotherapy is designed to specifically kill CD25+ regulatory T cells (Tregs) within solid tumors, once illuminated with 690nm nonthermal red light. 

 

For further information, refer to the detailed Cutaneous Squamous Cell Carcinoma Unmet Needs, Cutaneous Squamous Cell Carcinoma Market Drivers, and Cutaneous Squamous Cell Carcinoma Market Barriers, click here for Cutaneous Squamous Cell Carcinoma Ongoing Clinical Trial Analysis

 

Cutaneous Squamous Cell Carcinoma Emerging Drugs Profile

 

HLX 07: Shanghai Henlius Biotech

HLX07 is a bio-better independently developed by Henlius. Adopting the self-developed advanced antibody engineering platform, Henlius re-engineered cetuximab by humanizing its Fab regions and minimizing its glycan contents to generate HLX07 to reduce the immunogenicity and increase the affinity of the product. Pre-clinical studies have shown that HLX07 binds EGFR with similar affinity and had better bioactivity compared to cetuximab. Henlius holds patents of HLX07 in several jurisdictions including China, the United States, the European Union, Australia, and Japan. Moreover, Henlius has received clinical trial approvals for HLX07 in the treatment of solid tumors in Chinese mainland, the United States, and Taiwan China. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

 

Opzelura: Incyte Corporation

Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

 

RM 1995: Rakuten Medical

RM-1995, developed by Rakuten Medical using its IlluminoxTM platform, is an antibody-dye conjugate comprised of a monoclonal antibody specific for cell-surface interleukin 2 (IL-2) receptor α-chain (CD25) and IRDye® 700DX (IR700), a light-activatable dye. RM-1995 photo immunotherapy is designed to specifically kill CD25+ regulatory T cells (Tregs) within solid tumors, once illuminated with 690nm nonthermal red light. Rakuten Medical’s preclinical data has suggested that RM-1995 photo immunotherapy treatment can be utilized to specifically deplete intratumoral Tregs, thereby alleviating local Treg-mediated restraint within the tumor microenvironment, rapidly improving the CD8 T cell: Treg ratio, and reinvigorating effector CD8+ T cell responses. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

 

Cutaneous Squamous Cell Carcinoma Pipeline Therapeutics Assessment

 

There are approx. 45+ key companies which are developing the therapies for Cutaneous Squamous Cell Carcinoma. The companies which have their Cutaneous Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase II include, Incyte Corporation.

 

Request a sample and discover the recent advances in Cutaneous Squamous Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Cutaneous Squamous Cell Carcinoma Treatment Landscape

 

Scope of the Cutaneous Squamous Cell Carcinoma Pipeline Report

 

• Coverage- Global

 

• Cutaneous Squamous Cell Carcinoma Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.

 

• Cutaneous Squamous Cell Carcinoma Pipeline Therapies includes Cemiplimab, IBI318, STP705, Pembrolizumab, PEP005, and others.

 

• Cutaneous Squamous Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Cutaneous Squamous Cell Carcinoma Market Drivers and Cutaneous Squamous Cell Carcinoma Market Barriers, click here @ Cutaneous Squamous Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content 

1. Introduction
2. Executive Summary
3. Cutaneous Squamous Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cutaneous Squamous Cell Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HLX 07: Shanghai Henlius Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RM 1995: Rakuten Medical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name : Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cutaneous Squamous Cell Carcinoma Key Companies
21. Cutaneous Squamous Cell Carcinoma Key Products
22. Cutaneous Squamous Cell Carcinoma- Unmet Needs
23. Cutaneous Squamous Cell Carcinoma- Market Drivers and Barriers
24. Cutaneous Squamous Cell Carcinoma- Future Perspectives and Conclusion
25. Cutaneous Squamous Cell Carcinoma Analyst Views
26. Cutaneous Squamous Cell Carcinoma Key Companies
27. Appendix

 

Got Queries? Find out the related information on Cutaneous Squamous Cell Carcinoma Mergers and acquisitions, Cutaneous Squamous Cell Carcinoma Licensing Activities @ Cutaneous Squamous Cell Carcinoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/